![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MS Pharma becomes a partner for the commercialization of FYB203, Formycon’s Biosimilar to Eylea® (Aflibercept), in the MENA Region for the treatment of neovascular age-related macular degeneration.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: FYB203
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: MS Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 14, 2024
Details:
FYB203, a biosimilar candidate to Eylea (aflibercept), which Klinge Biopharma has in-licensed from the German biosimilar developer Formycon AG, is being evaluated in a Phase 3 clinical trial in patients with Neovascular (wet) Age-Related Macular Degeneration (nAMD).
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: FYB203
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: Undisclosed Upfront Cash: $32.5 million
Deal Type: Acquisition January 09, 2023